NASDAQ:ALLO Allogene Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Allogene Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $38.00 +0.82 (+2.21 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$36.58Now: $38.00▼$38.1550-Day Range$32.38MA: $35.61▼$38.9952-Week Range$17.43Now: $38.00▼$55.00Volume1.83 million shsAverage Volume847,651 shsMarket Capitalization$5.29 billionP/E RatioN/ADividend YieldN/ABeta1.67 ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; and ALLO-501, an allogeneic CAR T cell product candidate targeting CD19 to treat R/R non-Hodgkin lymphoma. Its preclinical product candidates include ALLO-715, an allogeneic CAR T cell product candidate for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; CD70 to treat renal cell cancer; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepletion agent. The company was founded in 2017 and is headquartered in South San Francisco, California.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingAllogene Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.69, and is based on 11 buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $47.92, Allogene Therapeutics has a forecasted upside of 26.1% from its current price of $38.00.Amount of Analyst CoverageAllogene Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesAllogene Therapeutics has received 210 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAllogene Therapeutics has received 239 “underperform” votes. (Add your “underperform” vote.)Community SentimentAllogene Therapeutics has received 53.23% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Allogene Therapeutics and other stocks. Vote “Outperform” if you believe ALLO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ALLO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAllogene Therapeutics does not currently pay a dividend.Dividend GrowthAllogene Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Allogene Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,327,446.00 in company stock.Percentage Held by InsidersOnly 31.30% of the stock of Allogene Therapeutics is held by insiders.Percentage Held by Institutions62.56% of the stock of Allogene Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Allogene Therapeutics are expected to decrease in the coming year, from ($2.16) to ($2.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Allogene Therapeutics is -18.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Allogene Therapeutics is -18.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAllogene Therapeutics has a P/B Ratio of 7.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.33 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALLO Previous Symbol CUSIPN/A CIKN/A Webwww.allogene.com Phone650-457-2700Debt Debt-to-Equity Ratio0.04 Current Ratio22.24 Quick Ratio22.24Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.16 per share Price / Book7.36Profitability EPS (Most Recent Fiscal Year)($1.83) Net Income$-184,590,000.00 Net MarginsN/A Return on Equity-30.11% Return on Assets-27.05%Miscellaneous Employees122 Outstanding Shares139,292,000Market Cap$5.29 billion Next Earnings Date11/3/2020 (Estimated) OptionableNot Optionable $38.00 +0.82 (+2.21 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ALLO News and Ratings via Email Sign-up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter. Allogene Therapeutics (NASDAQ:ALLO) Frequently Asked Questions How has Allogene Therapeutics' stock been impacted by COVID-19? Allogene Therapeutics' stock was trading at $25.05 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ALLO shares have increased by 51.7% and is now trading at $38.00. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Allogene Therapeutics? 16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allogene Therapeutics in the last year. There are currently 5 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Allogene Therapeutics. When is Allogene Therapeutics' next earnings date? Allogene Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020. View our earnings forecast for Allogene Therapeutics. How were Allogene Therapeutics' earnings last quarter? Allogene Therapeutics Inc (NASDAQ:ALLO) released its earnings results on Wednesday, August, 5th. The company reported ($0.53) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.54) by $0.01. View Allogene Therapeutics' earnings history. What price target have analysts set for ALLO? 16 equities research analysts have issued 12-month target prices for Allogene Therapeutics' shares. Their forecasts range from $27.00 to $70.00. On average, they anticipate Allogene Therapeutics' stock price to reach $47.92 in the next twelve months. This suggests a possible upside of 26.1% from the stock's current price. View analysts' price targets for Allogene Therapeutics. Who are some of Allogene Therapeutics' key competitors? Some companies that are related to Allogene Therapeutics include NOVOZYMES A/S/S (NVZMY), BioNTech (BNTX), argenx (ARGX), Qiagen (QGEN), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), Repligen (RGEN), Novavax (NVAX), Acceleron Pharma (XLRN), Adaptive Biotechnologies (ADPT), Momenta Pharmaceuticals (MNTA), Crispr Therapeutics (CRSP), Iovance Biotherapeutics (IOVA), China Biologic Products (CBPO) and Spark Therapeutics (ONCE). View all competitors. What other stocks do shareholders of Allogene Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Allogene Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Teladoc Health (TDOC), Bristol-Myers Squibb (BMY), Pfizer (PFE), Crispr Therapeutics (CRSP), Alibaba Group (BABA) and QUALCOMM (QCOM). Who are Allogene Therapeutics' key executives? Allogene Therapeutics' management team includes the following people: Mr. Joshua A. Kazam, Co-Founder & Director (Age 42)Dr. Arie S. Belldegrun F.A.C.S., M.D., FACS, Co-Founder & Exec. Chairman (Age 70)Dr. David D. Chang M.D., Ph.D., Co-Founder, Pres, CEO & Director (Age 59)Dr. Eric Thomas Schmidt Ph.D., Chief Financial Officer (Age 51)Dr. Alison Moore Ph.D., Chief Technical Officer (Age 52) When did Allogene Therapeutics IPO? (ALLO) raised $272 million in an initial public offering (IPO) on Thursday, October 11th 2018. The company issued 16,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies served as the underwriters for the IPO. What is Allogene Therapeutics' stock symbol? Allogene Therapeutics trades on the NASDAQ under the ticker symbol "ALLO." Who are Allogene Therapeutics' major shareholders? Allogene Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include TPG Group Holdings SBS Advisors Inc. (14.15%), Vanguard Group Inc. (4.22%), FMR LLC (2.09%), Regents of The University of California (1.02%), Victory Capital Management Inc. (0.85%) and Hillhouse Capital Advisors LTD. (0.57%). Company insiders that own Allogene Therapeutics stock include Alison Moore, Arie Belldegrun, David D Chang, Eric Thomas Schmidt, Group Holdings (Sbs) Advis Tpg and Veer Bhavnagri. View institutional ownership trends for Allogene Therapeutics. Which institutional investors are selling Allogene Therapeutics stock? ALLO stock was sold by a variety of institutional investors in the last quarter, including TPG Group Holdings SBS Advisors Inc., Regents of The University of California, FMR LLC, Capital Impact Advisors LLC, Tekla Capital Management LLC, Principal Financial Group Inc., Principal Financial Group Inc., and Man Group plc. Company insiders that have sold Allogene Therapeutics company stock in the last year include Alison Moore, David D Chang, Eric Thomas Schmidt, Group Holdings (Sbs) Advis Tpg, and Veer Bhavnagri. View insider buying and selling activity for Allogene Therapeutics. Which institutional investors are buying Allogene Therapeutics stock? ALLO stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Victory Capital Management Inc., Hillhouse Capital Advisors LTD., Nuveen Asset Management LLC, Nordea Investment Management AB, Gilder Gagnon Howe & Co. LLC, Charles Schwab Investment Management Inc., and Blackstone Group Inc. Company insiders that have bought Allogene Therapeutics stock in the last two years include Arie Belldegrun, David D Chang, and Group Holdings (Sbs) Advis Tpg. View insider buying and selling activity for Allogene Therapeutics. How do I buy shares of Allogene Therapeutics? Shares of ALLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Allogene Therapeutics' stock price today? One share of ALLO stock can currently be purchased for approximately $38.00. How big of a company is Allogene Therapeutics? Allogene Therapeutics has a market capitalization of $5.29 billion. The company earns $-184,590,000.00 in net income (profit) each year or ($1.83) on an earnings per share basis. Allogene Therapeutics employs 122 workers across the globe. What is Allogene Therapeutics' official website? The official website for Allogene Therapeutics is www.allogene.com. How can I contact Allogene Therapeutics? Allogene Therapeutics' mailing address is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-457-2700 or via email at [email protected] This page was last updated on 9/19/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
